New drug for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new drug called SRT-017 for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The drug targets a marker on cancer cells (PSMA) and may help slow the disease. The study will check if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with prostate cancer that has spread and is no longer responding to standard hormone therapy.
- You have tried at least one newer hormone drug (like abiraterone, enzalutamide, apalutamide, or darolutamide) and the cancer kept growing.
- A special scan (PSMA-PET) shows your cancer is PSMA-positive, meaning it has a marker this drug targets.
- You have at least one measurable tumor or a bone metastasis.
- You are generally in good health (able to care for yourself, with a performance status of 0 or 1) and have adequate organ function.
- You haven't had certain previous treatments like radioisotope therapy in the last 6 months or external radiation in the last 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.